LakeShore Biopharma Valuation
| LSBPW Stock | 0.07 0.01 22.73% |
LakeShore Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of LakeShore Biopharma Co, from analyzing the firm fundamentals such as Number Of Shares Shorted of 23.24 K, return on equity of -0.66, and Profit Margin of (0.76) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that LakeShore Biopharma's price fluctuation is out of control at this time. Calculation of the real value of LakeShore Biopharma Co, is based on 3 months time horizon. Increasing LakeShore Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the LakeShore stock is determined by what a typical buyer is willing to pay for full or partial control of LakeShore Biopharma Co,. Since LakeShore Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of LakeShore Stock. However, LakeShore Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0675 | Real 0.0558 | Hype 0.07 |
The intrinsic value of LakeShore Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence LakeShore Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of LakeShore Biopharma Co, helps investors to forecast how LakeShore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of LakeShore Biopharma more accurately as focusing exclusively on LakeShore Biopharma's fundamentals will not take into account other important factors: LakeShore Biopharma Total Value Analysis
LakeShore Biopharma Co, is now projected to have takeover price of 0 with market capitalization of 0, debt of 424.46 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the LakeShore Biopharma fundamentals before making investing decisions based on enterprise value of the companyLakeShore Biopharma Investor Information
The company had not issued any dividends in recent years. Based on the key measurements obtained from LakeShore Biopharma's financial statements, LakeShore Biopharma Co, is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.LakeShore Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. LakeShore Biopharma has an asset utilization ratio of 37.9 percent. This indicates that the Company is making USD0.38 for each dollar of assets. An increasing asset utilization means that LakeShore Biopharma Co, is more efficient with each dollar of assets it utilizes for everyday operations.LakeShore Biopharma Profitability Analysis
The company reported the revenue of 573.42 M. Net Loss for the year was (433.46 M) with profit before overhead, payroll, taxes, and interest of 386.06 M.About LakeShore Biopharma Valuation
Our relative valuation model uses a comparative analysis of LakeShore Biopharma. We calculate exposure to LakeShore Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of LakeShore Biopharma's related companies.LakeShore Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as LakeShore Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 10.7 M |
Additional Tools for LakeShore Stock Analysis
When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.